BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
Phase 1
Completed
- Conditions
- Liver DysfunctionLiver InsufficiencyHepatic FailureMyocardial FailureHeart DecompensationCardiac FailureCongestive Heart Failure
- Interventions
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT03515980
- Locations
- 🇵🇱
KO-MED Centra Kliniczne Lublin, Lublin, Poland
🇭🇺Semmelweis Egyetem Altalanos Orvostudomanyi Kar, Budapest, Hungary
🇵🇱BioVirtus Centrum Medyczne, Jozefow, Poland
A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)
- Conditions
- Heart Failure
- First Posted Date
- 2018-05-03
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 99209
- Registration Number
- NCT03515655
- Locations
- 🇺🇸
Local Institution, Princeton, New Jersey, United States
Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 94
- Registration Number
- NCT03509883
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Completed
- Conditions
- Chronic Myeloid Leukemia in Chronic PhasePhiladelphia ChromosomeChronic Myeloid Leukemia
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 463
- Registration Number
- NCT03509896
- Locations
- 🇨🇳
Local Institution, Tianjin, Tianjin, China
Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)
Withdrawn
- Conditions
- Non-valvular Atrial Fibrillation
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03508258
- Locations
- 🇺🇸
Local Institution, Bethesda, Maryland, United States
Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure
Completed
- Conditions
- Atrial FibrillationHeart Failure
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60000
- Registration Number
- NCT03508271
- Locations
- 🇺🇸
Local Institution, Ann Arbor, Michigan, United States
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer
Completed
- Conditions
- Non-small Cell Lung Cancer NSCLCSmall Cell Lung Cancer SCLCLung Cancer
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6205
- Registration Number
- NCT03505515
- Locations
- 🇨🇳
Local Institution, Shanghai, SHG, China
Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma
Completed
- Conditions
- Melanoma
- Interventions
- Other: Non-interventional
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT03504696
- Locations
- 🇫🇷
Local Institution, Nantes Cedex 1, France
Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)
Terminated
- Conditions
- Chronic Hepatitis C
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT03500562
- Locations
- 🇨🇳
Local Institution, Guangzhou, Guangdong, China
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT03496168
- Locations
- 🇺🇸
Local Institution - 0003, Scottsdale, Arizona, United States
🇺🇸Local Institution - 0001, New Haven, Connecticut, United States
🇺🇸Local Institution - 0004, Durham, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath